Marco Andreani

ORCID: 0000-0003-3451-3624
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immune Cell Function and Interaction
  • T-cell and B-cell Immunology
  • Hematopoietic Stem Cell Transplantation
  • Immunotherapy and Immune Responses
  • Hemoglobinopathies and Related Disorders
  • Monoclonal and Polyclonal Antibodies Research
  • Immunodeficiency and Autoimmune Disorders
  • Renal Transplantation Outcomes and Treatments
  • Prenatal Screening and Diagnostics
  • Blood groups and transfusion
  • Genomics and Rare Diseases
  • RNA modifications and cancer
  • CAR-T cell therapy research
  • Cell Adhesion Molecules Research
  • Organ Transplantation Techniques and Outcomes
  • Erythrocyte Function and Pathophysiology
  • Transplantation: Methods and Outcomes
  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • Myasthenia Gravis and Thymoma
  • Pancreatic function and diabetes
  • Immune Response and Inflammation
  • Polyomavirus and related diseases
  • Diabetes and associated disorders
  • Mesenchymal stem cell research

Bambino Gesù Children's Hospital
2018-2025

Istituti di Ricovero e Cura a Carattere Scientifico
2006-2025

Areté Associates (United States)
2023-2024

Immungenetics (Germany)
2014-2021

Laboratory of Molecular Genetics
2021

Policlinico Tor Vergata
2009-2018

Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione
2007-2018

Fondazione Roma
2015-2018

University of Rome Tor Vergata
2007-2014

Pirelli (Italy)
2006

With the aim to individuate alleles that may reflect a higher susceptibility disease, in present study we analyzed HLA allele frequency distribution group of 99 Italian patients affected by severe or extremely form COVID-19. After application Bonferroni's correction for multiple tests, significant association was found HLA-DRB1*15:01, -DQB1*06:02 and -B*27:07, after comparing results reference 1017 individuals, previously typed our laboratory. The increased frequencies observed contribute...

10.1111/tan.14047 article EN cc-by HLA 2020-08-22

HLA genotyping by next‐generation sequencing is now widely performed. We aimed at evaluating the performance of One Lambda AllType kit using Thermo Fisher Scientific reagents on Ion S5 XL platform. Reads were analyzed TypeStream Visual software. performed 15 runs between April and September 2018 to type DNA HLA‐A/B/C/DRB1/3/4/5/DQA1/DQB1/DPA1/DPB1 loci from 340 samples positive controls. observed only seven (0.1%) critical mistakes among 6009 alleles typed, corresponding two allele dropouts,...

10.1111/tan.13708 article EN HLA 2019-10-02

ABSTRACT HLA‐DQA1*01:67:02 differs from HLA‐DQA1*01:67:01 by one nucleotide substitution in codon 229 exon 4.

10.1111/tan.70084 article EN HLA 2025-02-01

Patients with homozygous beta-thalassemia, who have a good prognosis during treatment conventional therapy, appear to an especially high probability of hematologic cure bone marrow transplantation, although the morbidity and mortality associated such are not established.

10.1056/nejm199309163291204 article EN New England Journal of Medicine 1993-09-16

IL-10-producing CD4(+) type 1 regulatory T (Tr1) cells, defined based on their ability to produce high levels of IL-10 in the absence IL-4, are major players induction and maintenance peripheral tolerance. Tr1 cells inhibit T-cell responses mainly via cytokine-dependent mechanisms. The cellular molecular mechanisms underlying suppression APC by still not completely elucidated. Here, we that specifically lyse myeloid through a granzyme B (GZB)- perforin (PRF)-dependent mechanism requires HLA...

10.1002/eji.201041120 article EN European Journal of Immunology 2011-04-06

Background Persistent mixed chimerism represents a state in which recipient and donor cells stably co-exist after hematopoietic stem cell transplantation. However, since most of the studies reported literature engraftment was observed nucleated cells, this study we determined origin mature erythrocytes patients with persistent transplantation for hemoglobinopathies. Results were compared singly picked out burst-forming unit – erythroid colonies collected from peripheral blood bone...

10.3324/haematol.2010.031013 article EN cc-by-nc Haematologica 2010-10-07

Background A catalogue of common and well‐documented (CWD) human leukocyte antigen (HLA), previously established by the American Society for Histocompatibility Immunogenetics (ASHI), is widely used as indicator typing ambiguities to be resolved in tissue transplantation or checking universality any HLA allele world. However, European population samples, which are characterized a substantial level genetic variation, underrepresented ASHI catalogue. Therefore, Population Genetics Working Group...

10.1111/tan.12956 article EN HLA 2017-01-18

Current regular blood transfusion programs and chelation treatment have considerably improved survival of patients with thalassemia, which resulted in a larger proportion adult patients. However, disease- treatment-related complications these progress over time, causing severe morbidity shortened life expectancy. Stem cell transplantation still remains the only cure currently available for thalassemia. This study updates transplant outcomes 107 median age 22 years (range, 17-35 years) who...

10.1196/annals.1345.024 article EN Annals of the New York Academy of Sciences 2005-11-01

We have reported that immunization of H-2k mice with lymphoid cells from various allogeneic strains induced a population could eliminate first-passage spontaneous AKR leukemia the spleens immuno-suppressed (H-2k) hosts. In present study, we examined nature responsible for this graft-vs-leukemia (GVL) reaction and compared them to cytolytic detected in vitro. Spleen alloimmunized CBA/J were selectively depleted subpopulations by treatment antibody complement (C), then tested vivo GVL...

10.4049/jimmunol.131.4.2050 article EN The Journal of Immunology 1983-10-01
Coming Soon ...